AKRO
Price
$41.13
Change
+$1.52 (+3.84%)
Updated
Apr 24, 04:49 PM (EDT)
Capitalization
3.07B
26 days until earnings call
MDGL
Price
$320.09
Change
+$11.30 (+3.66%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
6.82B
19 days until earnings call
Ad is loading...

AKRO vs MDGL

Header iconAKRO vs MDGL Comparison
Open Charts AKRO vs MDGLBanner chart's image
Akero Therapeutics
Price$41.13
Change+$1.52 (+3.84%)
Volume$1.5K
Capitalization3.07B
Madrigal Pharmaceuticals
Price$320.09
Change+$11.30 (+3.66%)
Volume$4.24K
Capitalization6.82B
AKRO vs MDGL Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. MDGL commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Buy and MDGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (AKRO: $39.61 vs. MDGL: $308.79)
Brand notoriety: AKRO and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 112% vs. MDGL: 95%
Market capitalization -- AKRO: $3.07B vs. MDGL: $6.82B
AKRO [@Biotechnology] is valued at $3.07B. MDGL’s [@Biotechnology] market capitalization is $6.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, AKRO is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • AKRO’s TA Score: 5 bullish, 5 bearish.
  • MDGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AKRO is a better buy in the short-term than MDGL.

Price Growth

AKRO (@Biotechnology) experienced а +5.80% price change this week, while MDGL (@Biotechnology) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.74%. For the same industry, the average monthly price growth was -5.54%, and the average quarterly price growth was -12.32%.

Reported Earning Dates

AKRO is expected to report earnings on Aug 08, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.82B) has a higher market cap than AKRO($3.07B). AKRO YTD gains are higher at: 42.380 vs. MDGL (0.071). AKRO has higher annual earnings (EBITDA): -247.37M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. AKRO (743M). AKRO has less debt than MDGL: AKRO (36.5M) vs MDGL (120M). MDGL has higher revenues than AKRO: MDGL (180M) vs AKRO (0).
AKROMDGLAKRO / MDGL
Capitalization3.07B6.82B45%
EBITDA-247.37M-450.12M55%
Gain YTD42.3800.07159,441%
P/E RatioN/AN/A-
Revenue0180M-
Total Cash743M926M80%
Total Debt36.5M120M30%
FUNDAMENTALS RATINGS
AKRO vs MDGL: Fundamental Ratings
AKRO
MDGL
OUTLOOK RATING
1..100
1457
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
5730
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
3844
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a31

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (49) in the null industry is in the same range as MDGL (67) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is in the same range as AKRO (57) in the null industry. This means that MDGL’s stock grew similarly to AKRO’s over the last 12 months.

AKRO's SMR Rating (91) in the null industry is in the same range as MDGL (95) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDGL’s over the last 12 months.

AKRO's Price Growth Rating (38) in the null industry is in the same range as MDGL (44) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDGL’s over the last 12 months.

AKRO's P/E Growth Rating (100) in the null industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 17 days ago
84%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGISX33.18N/A
N/A
Virtus Duff & Phelps Glb Rl Estt Secs I
RFNBX73.98N/A
N/A
American Funds Fundamental Invs R2
NECCX11.79N/A
N/A
Natixis US Equity Opportunities C
BEXIX15.34N/A
N/A
Baron Emerging Markets Institutional
NPSGX13.26N/A
N/A
Nicholas Partners Small Cap Gr Instl